A randomized, double-blind, placebo-controlled, multicenter, parallel-group phase 3 study to determine the efficacy and safety of retigabine (1200 mg/day) used as adjunctive therapy in refractory epilepsy patients with partial-onset seizures.

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, parallel-group phase 3 study to determine the efficacy and safety of retigabine (1200 mg/day) used as adjunctive therapy in refractory epilepsy patients with partial-onset seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Retigabine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESTORE-1
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Sep 2011 Results presented at the 29th International Epilepsy Congress.
    • 30 Mar 2011 Results published in the Neurology.
    • 03 Dec 2010 Results presented as an abstract at the 64th Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top